Cisplatin is chemotherapy, anti cancer drug for infusion indicated as palliative therapy, to be employed either as a single agent or in established combination therapy with other chemotherapeutic agents in the following indications:
- Metastatic Testicular Tumors
In established combination therapy with other approved chemotherapeutic agents, in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. - Metastatic Ovarian Tumors
In established combination therapy with other approved chemotherapeutic agents, in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide.
Cisplatin, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy that have not previously received cisplatin therapy. - Advanced Bladder Cancer
Cisplatin is indicated as a single agent for patients with transitional cell bladder cancer, which is no longer amenable to local treatments such as surgery and/or radiotherapy
